ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P981 | DOI: 10.1530/endoabs.63.P981

Effectiveness and tolerance of liraglutide and bupropion/naltrexone: clinical experience

Jersy Jair Cardenas-Salas1,2, Bogdana Luiza Luca1, Alberto Aliaga-Verdugo3, Teresa Montoya-Álvarez2, Sonsoles Gutierrez-Medina4, Roberto Sierra-Poyatos1, Maria Alba Galdón Sanz-Pastor1 & Clotilde Vázquez Martínez1


1Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain; 2Hospital Universitario Infanta Elena, Madrid, Spain; 3Hospital Quirónsalud Sagrado Corazón, Sevilla, Spain; 4Hospital Universitario Rey Juan Carlos, Madrid, Spain.


Introduction: Different pharmacological therapies for obesity have become available in the last years. It is important to know their effectiveness in real-world practice and their acceptance among patients.

Objectives: To analyze the anthropometric changes, daily dosis, side effects and treatment withdrawal in patients treated with Liraglutide or Naltrexone/Bupropion in clinical practice.

Material and methods: Retrospective descriptive study. We analysed the percentage of weight loss, side effects and withdrawal causes in patients treated with Liraglutide or Naltrexone/Bupropion after 1, 3, 6 and 12 months.

Results: Hundred patients were included. Baseline characteristics are shown in TABLE. The daily dosis of Liraglutide (mg) were: 0.6 (1.2%), 0.9 (1.2%), 1.2 (25.3%), 1.8 (36.1%), 2.1 (1.2%), 2.4 (13.25%) and 3.0 (20.48%). Daily dose of Naltrexone/Bupropion (mg) were: 8/90 (11.76%), 16/180 (11.76%), 24/270(17.65%) and 32/360 (58.8%). The % of weight loss were: for Liraglutide −3.4%, −6.1%, −6.9% and −7% at 1, 3, 6 and 12 months (P<0.05 for all); for Naltrexone/Bupropion −4.1% and −5.7% at 1 and 3 months (P<0.05) and −5.6% at 6 months (P=0.08). There were no differences in the % of weight loss between high (>1.8 mg) and low (≤1.8 mg) Liraglutide dose. Withdrawal percentage was: 25.3% with Liraglutide, especially due to economic reasons (28.5%), lack of effectiveness (23.8%) or side effects (19%); 29.4% with Naltrexone/Bupropion especially due to side effects (60%) or lack of effectiveness (25%). Side effects were reported in 52.54% patients treated with Liraglutide, the most common being gastrointestinal effects. One patient had depression symptoms that needed treatment and ceased after Liraglutide withdrawal. 66.7% of patients treated with Naltrexone/Bupropion reported side effects, the most common being nausea, headache, dry mouth or dizziness.

Table 1
Liraglutide (N=83)Naltrexone/Bupropion (N=17)
Age (years)52.1±12.849.4±13.4
Women62.4%83.3%
Hypertension37.3%16.6%
Diabetes4.8%0%
Pre-Diabetes38.6%61.1%
Dyslipidemia36.1%11.1%
Obstructive-Sleep-Apnea25.3%23.5%
Weight(kg)101.1±17.4110.2±20.2
BMI (kg/m2)37.2±4.741.4±6.3
Waist Circumference (cm)116.2±14.0123.6±13.6
Glucose (mg/dl)95.2±9.995.7±10.8

Conclusions: We observed a significant loss of weight after Liraglutide treatment. Weight loss in Naltrexone/Bupropion group was only significant for the first 3 months. Most of patients in Liraglutide group used <3mg/day, mainly for economic reasons. The percentage of withdrawal was relatively high in both groups, especially due to side effects in Naltrexone/Bupropion and to price or lack of effectiveness in Liraglutide group.